Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1488)	3/1/2000 9:48:00 AM
From: nigel bates	Respond to of 4974

Is this to provide for paying off Amersham (gg) ? Where there is demand - March 1 /PRNewswire/ -- Abgenix, Inc. (Nasdaq: ABGX - news) today announced the sale of 450,000 shares of Common Stock at a price of $210 per share pursuant to the exercise of the underwriters' over-allotment option. March 1, 2000--Computerized Thermal Imaging, Inc. (OTC BB COII) announced today the close of its first private placement. Heavy interest in CTI generated significant funds in excess of the $30 million target. Cell Genesys, Inc. (Nasdaq: CEGE - news) today announced that the company has received net proceeds of approximately $25 million in connection with the exercise of an over-allotment option by the underwriters of the February 10, 2000 secondary stock offering by Abgenix, Inc. - supply follows pretty quickly. nig

To: scaram(o)uche who wrote (1488)	3/1/2000 1:27:00 PM
From: nigel bates	Read Replies (1) \| Respond to of 4974

...to put it in context (of sorts), Nycomed Amersham added $6bn to their market cap today, & they still don't seem to have decided what they are doing with their life sciences division... nig

To: scaram(o)uche who wrote (1488)	3/3/2000 8:47:00 AM
From: nigel bates	Read Replies (2) \| Respond to of 4974

This really boggles - March 3, 2000--PE Corp. today announced the exercise by its underwriters of an over-allotment option to purchase 570,000 shares of Celera Genomics common stock associated with its follow-on stock offering announced March 1, 2000. Including the over-allotment, the public offering totaled 4,370,000 shares at $225.00 per share, with net proceeds expected to be approximately $944 million. The appetite for stock clearly NOT satiated. Note MEDX raising funds today too. nig